ALTAY THERAPEUTICS CLOSES $37 MILLION SERIES A FINANCING TO ADVANCE FIRST ORAL DUX4 INHIBITOR FOR FSHD INTO THE CLINIC

Reuters · 2d ago

Please log in to view news